FI924069A - Terapeutiskt anvaendbara peptider och peptidfragment - Google Patents

Terapeutiskt anvaendbara peptider och peptidfragment Download PDF

Info

Publication number
FI924069A
FI924069A FI924069A FI924069A FI924069A FI 924069 A FI924069 A FI 924069A FI 924069 A FI924069 A FI 924069A FI 924069 A FI924069 A FI 924069A FI 924069 A FI924069 A FI 924069A
Authority
FI
Finland
Prior art keywords
peptidfragment
peptider
och
terapeutiskt anvaendbara
terapeutiskt
Prior art date
Application number
FI924069A
Other languages
English (en)
Other versions
FI108139B (fi
FI924069A0 (fi
Inventor
Gustav Gaudernack
Tobias Gedde-Dahl
Jon Amund Eriksen
Original Assignee
Norsk Hydro As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Norsk Hydro As filed Critical Norsk Hydro As
Publication of FI924069A publication Critical patent/FI924069A/fi
Publication of FI924069A0 publication Critical patent/FI924069A0/fi
Application granted granted Critical
Publication of FI108139B publication Critical patent/FI108139B/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4746—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used p53
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/806—Antigenic peptides or proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
FI924069A 1991-02-26 1992-09-11 Menetelmä terapeuttisesti käyttökelpoisen peptidin valmistamiseksi FI108139B (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB919103974A GB9103974D0 (en) 1991-02-26 1991-02-26 Therapeutically useful peptides or peptide fragments
GB9103974 1991-02-26
PCT/NO1992/000032 WO1992014756A1 (en) 1991-02-26 1992-02-21 Therapeutically useful peptides and peptides fragments
NO9200032 1992-02-21

Publications (3)

Publication Number Publication Date
FI924069A true FI924069A (fi) 1992-09-11
FI924069A0 FI924069A0 (fi) 1992-09-11
FI108139B FI108139B (fi) 2001-11-30

Family

ID=10690575

Family Applications (1)

Application Number Title Priority Date Filing Date
FI924069A FI108139B (fi) 1991-02-26 1992-09-11 Menetelmä terapeuttisesti käyttökelpoisen peptidin valmistamiseksi

Country Status (14)

Country Link
US (1) US5961978A (fi)
EP (1) EP0529023B1 (fi)
AT (1) ATE181337T1 (fi)
AU (1) AU660452B2 (fi)
CA (1) CA2077537C (fi)
DE (1) DE69229428T2 (fi)
DK (1) DK0529023T3 (fi)
ES (1) ES2134797T3 (fi)
FI (1) FI108139B (fi)
GB (2) GB9103974D0 (fi)
GR (1) GR3031234T3 (fi)
HK (1) HK1011370A1 (fi)
NO (1) NO923953L (fi)
WO (1) WO1992014756A1 (fi)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2124595A1 (en) * 1992-09-30 1994-04-14 Hanswalter Zentgraf Process for detecting p53-specific antibodies
AU6363094A (en) * 1993-03-15 1994-10-11 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Peptide coated dendritic cells as immunogens
AT399656B (de) * 1993-03-19 1995-06-26 Boehringer Ingelheim Int Verfahren zur herstellung von krebsvakzinen
GB9422814D0 (en) * 1994-11-11 1995-01-04 Medinnova Sf Chemical method
US6156316A (en) * 1995-05-08 2000-12-05 Sloan-Kettering Institute For Cancer Research Oncogene fusion protein peptide vaccines
US6365151B1 (en) 1996-01-19 2002-04-02 Philadelphia Health And Educational Corporation Cellular immunogens comprising cognate proto-oxogenes
WO1997040156A1 (en) 1996-04-19 1997-10-30 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Mutated ras peptides for generation of cd8+ cytotoxic t lymphocytes
US7709002B1 (en) * 1996-04-19 2010-05-04 The United States Of America As Represented By The Department Of Health And Human Services Mutated ras peptides for generation of CD8+Cytotoxic T lymphocytes
US6069229A (en) * 1997-03-07 2000-05-30 Schering Corporation Mammalian proteinases; oxidoreductases; related reagents
GB2328689A (en) * 1997-08-27 1999-03-03 Norsk Hydro As Peptides based on the p21 ras proto-oncogene protein for the treatment of cancer
NO315238B1 (no) 1998-05-08 2003-08-04 Gemvax As Peptider som stammer fra leserammeforskyvingsmutasjoner i TBF<beta>II- eller BAX-genet, og farmasöytiske sammensetninger inneholdende disse,nukleinsyresekvenser som koder for slike peptider, plasmider og virusvektoreromfattende slikenukleinsy
NO314086B1 (no) 1998-05-08 2003-01-27 Gemvax As Peptider og farmasöytiske sammensetninger inneholdende disse, nukleinsyresekvenser som koder for slike peptider, plasmider og virusvektoreromfattende slike DNA-sekvenser samt anvendelse av disse for fremstilling avfarmasöytiske preparater til
US7030211B1 (en) 1998-07-08 2006-04-18 Gemvax As Antigenic peptides derived from telomerase
NO309798B1 (no) * 1999-04-30 2001-04-02 Targovax As Peptidblanding, samt farmasoytisk sammensetning og kreftvaksine som innbefatter peptidblandingen
US7700359B2 (en) * 2000-06-02 2010-04-20 Novartis Vaccines And Diagnostics, Inc. Gene products differentially expressed in cancerous cells
WO2003057926A1 (en) * 2002-01-08 2003-07-17 Chiron Corporation Gene products differentially expressed in cancerous breast cells and their methods of use
GB0031430D0 (en) 2000-12-22 2001-02-07 Norsk Hydro As Polypeptides
GB0105238D0 (en) * 2001-03-02 2001-04-18 Norsk Hydro As Vaccines
US20030206916A1 (en) * 2002-05-03 2003-11-06 Rush-Presbyterian-St. Luke's Medical Center Immunogenic peptides
US7439042B2 (en) * 2002-12-16 2008-10-21 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis C infection
CN104147597A (zh) * 2002-12-16 2014-11-19 全球免疫股份有限公司 用于免疫治疗的基于酵母的疫苗
US8343502B2 (en) 2002-12-16 2013-01-01 Globeimmune, Inc. Yeast-based vaccines as immunotherapy
WO2006044923A2 (en) * 2004-10-18 2006-04-27 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis c infection
US9732131B2 (en) 2006-02-27 2017-08-15 Calviri, Inc. Identification and use of novopeptides for the treatment of cancer
TW200806789A (en) * 2006-03-27 2008-02-01 Globeimmune Inc RAS mutation and compositions and methods related thereto
US20080079547A1 (en) * 2006-09-29 2008-04-03 Sensormatic Electronics Corporation Radio frequency identification reader having a signal canceller and method thereof
EP2331125A4 (en) 2008-09-19 2013-03-27 Globeimmune Inc IMMUNOTHERAPY FOR CHRONIC HEPATITIS C-VIRUS INFECTIONS
GB0821616D0 (en) 2008-11-26 2008-12-31 Lytix Biopharma As Compounds
EP3363457A1 (en) 2013-12-09 2018-08-22 Targovax Asa A peptide mixture
AU2015257774B2 (en) * 2014-05-06 2018-12-20 Targovax Solutions AS Peptide vaccine comprising mutant RAS peptide and chemotherapeutic agent
CA3051252A1 (en) 2017-02-01 2018-08-09 Modernatx, Inc. Immunomodulatory therapeutic mrna compositions encoding activating oncogene mutation peptides
CN110709094A (zh) * 2017-02-03 2020-01-17 威斯康星州医药大学股份有限公司 Kras肽疫苗组合物及其使用方法
US20200276285A1 (en) 2017-06-02 2020-09-03 Arizona Board Of Regents On Behalf Of Arizona State University A method to create personalized cancer vaccines
US12025615B2 (en) 2017-09-15 2024-07-02 Arizona Board Of Regents On Behalf Of Arizona State University Methods of classifying response to immunotherapy for cancer
BR112020017645A2 (pt) * 2018-03-02 2020-12-29 Elicio Therapeutics Inc. Compostos que incluem uma sequência kras mutante e um lipídio e usos dos mesmos
CN114681600A (zh) * 2018-10-19 2022-07-01 杭州纽安津生物科技有限公司 通用性多肽疫苗及其在制备治疗/预防胰腺癌药物中的应用
EP4038222A4 (en) 2019-10-02 2023-10-18 Arizona Board of Regents on behalf of Arizona State University METHODS AND COMPOSITIONS FOR IDENTIFYING NEOANTIGENS FOR USE IN THE TREATMENT AND PREVENTION OF CANCER
US11058751B1 (en) 2020-11-20 2021-07-13 Think Therapeutics, Inc. Compositions for optimized RAS peptide vaccines
US11421015B2 (en) 2020-12-07 2022-08-23 Think Therapeutics, Inc. Method of compact peptide vaccines using residue optimization
US11464842B1 (en) 2021-04-28 2022-10-11 Think Therapeutics, Inc. Compositions and method for optimized peptide vaccines using residue optimization

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE56509B1 (en) * 1982-11-04 1991-08-28 Univ California Methods for oncogenic detection
CA1219232A (en) * 1983-08-17 1987-03-17 Richard A. Lerner Polypeptide-induced monoclonal receptors to protein ligands
US4898932A (en) * 1985-01-29 1990-02-06 E. I. Du Pont De Nemours And Company Monoclonal antibodies reactive with activated and oncogenic ras p21 proteins
CA1296660C (en) * 1985-01-29 1992-03-03 Walter P. Carney Monoclonal antibody against a ras oncogene p21 related dodecapeptide
US5100664A (en) * 1985-09-20 1992-03-31 Cetus Corporation Human IL-2 as a vaccine adjuvant
DK354487A (da) * 1986-07-11 1988-01-12 Noboru Yanaihara Oncogen-relaterede peptider
CA1339069C (en) * 1987-11-09 1997-07-29 Henry Lee Niman Polypeptide-induced monoclonal receptors to protein ligand
US4957859A (en) * 1988-02-16 1990-09-18 Hoffmann-La Roche Inc. Antibodies for transforming ras protein
EP0370012A1 (en) * 1988-03-08 1990-05-30 E.I. Du Pont De Nemours And Company Monoclonal antibodies reactive with activated and oncogenic ras p21 proteins
JPH0816679B2 (ja) * 1988-04-22 1996-02-21 オンコジーン・サイエンス・インコーポレーテッド 体液および組織におけるｒａｓタンパクの検出、定量および分類
EP0354808B1 (en) * 1988-08-12 1997-12-03 Ligand Pharmaceuticals Incorporated Polypeptide-induced monoclonal receptors to protein ligands
ATE120860T1 (de) * 1990-01-26 1995-04-15 Washington Res Found Immunreaktivität gegenüber exprimierten aktivierten oncogenen zur diagnose und behandlung von bösartigen geschwülsten.

Also Published As

Publication number Publication date
AU660452B2 (en) 1995-06-29
NO923953D0 (no) 1992-10-12
CA2077537A1 (en) 1992-08-27
WO1992014756A1 (en) 1992-09-03
CA2077537C (en) 2000-06-13
ATE181337T1 (de) 1999-07-15
GB9103974D0 (en) 1991-04-10
FI108139B (fi) 2001-11-30
EP0529023A1 (en) 1993-03-03
DK0529023T3 (da) 2000-01-17
EP0529023B1 (en) 1999-06-16
GB9204098D0 (en) 1992-04-08
FI924069A0 (fi) 1992-09-11
US5961978A (en) 1999-10-05
DE69229428T2 (de) 2000-06-29
GR3031234T3 (en) 1999-12-31
HK1011370A1 (en) 1999-07-09
DE69229428D1 (de) 1999-07-22
GB2253211A (en) 1992-09-02
NO923953L (no) 1993-03-26
ES2134797T3 (es) 1999-10-16
AU1272992A (en) 1992-09-15

Similar Documents

Publication Publication Date Title
FI924069A (fi) Terapeutiskt anvaendbara peptider och peptidfragment
DK0585943T3 (da) Opløselige ligander for CD40
DK0668781T3 (da) Lymfokingenterapi af cancer i kombination med tumorantigener
ATE212540T1 (de) Antitumorvakzine
EP0541692A4 (en) Herpes simplex virus vp16 vaccines
NZ238833A (en) Equine herpesvirus-4 gh or gc polypeptides, nucleic acids encoding them and vaccines therefrom
GB0004576D0 (en) Proteins
ATE385809T1 (de) Saponin-zusammensetzungen und deren verwendung
ATE69549T1 (de) Erzeugnisse, enthaltend gallopamil und prazosin.
CY1108761T1 (el) Απενεργοποιημενες κυτοκινες για ανοσοποιηση
NO20000976L (no) Peptider
DK0427633T3 (da) Anvendelse af et polypeptid med gammainterferonaktivitet til fremstilling af farmaceutiske præparater beregnet til behandling af primitiv pleuracancer

Legal Events

Date Code Title Description
PC Transfer of assignment of patent

Owner name: GEMVAX AS

Free format text: GEMVAX AS